Green Alpha Advisors LLC Invests $288,000 in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Green Alpha Advisors LLC bought a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 27,231 shares of the biotechnology company's stock, valued at approximately $288,000. Green Alpha Advisors LLC owned approximately 0.10% of Arcturus Therapeutics as of its most recent SEC filing.

A number of other large investors have also modified their holdings of ARCT. Balyasny Asset Management L.P. purchased a new stake in shares of Arcturus Therapeutics during the fourth quarter worth $9,312,000. Schonfeld Strategic Advisors LLC grew its holdings in shares of Arcturus Therapeutics by 129.7% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 849,081 shares of the biotechnology company's stock valued at $14,409,000 after purchasing an additional 479,482 shares during the period. J. Goldman & Co LP purchased a new stake in shares of Arcturus Therapeutics in the fourth quarter valued at about $5,024,000. MPM Bioimpact LLC grew its holdings in shares of Arcturus Therapeutics by 109.5% in the fourth quarter. MPM Bioimpact LLC now owns 459,943 shares of the biotechnology company's stock valued at $7,805,000 after purchasing an additional 240,435 shares during the period. Finally, Empire Life Investments Inc. grew its holdings in shares of Arcturus Therapeutics by 85.5% in the fourth quarter. Empire Life Investments Inc. now owns 279,463 shares of the biotechnology company's stock valued at $4,742,000 after purchasing an additional 128,771 shares during the period. Hedge funds and other institutional investors own 94.54% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on ARCT shares. Wells Fargo & Company dropped their price objective on shares of Arcturus Therapeutics from $50.00 to $45.00 and set an "overweight" rating for the company in a report on Wednesday, May 14th. BTIG Research set a $48.00 price objective on shares of Arcturus Therapeutics and gave the company a "buy" rating in a report on Monday, March 10th. Scotiabank began coverage on shares of Arcturus Therapeutics in a research report on Wednesday, May 28th. They issued a "sector outperform" rating and a $32.00 target price on the stock. Canaccord Genuity Group decreased their target price on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Finally, Wall Street Zen raised shares of Arcturus Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Arcturus Therapeutics currently has an average rating of "Buy" and a consensus price target of $53.50.

Arcturus Therapeutics Stock Performance

Shares of ARCT traded down $0.05 during mid-day trading on Thursday, hitting $12.21. 211,886 shares of the company's stock were exchanged, compared to its average volume of 448,646. The company has a market cap of $331.15 million, a price-to-earnings ratio of -5.50 and a beta of 2.36. Arcturus Therapeutics Holdings Inc. has a fifty-two week low of $8.04 and a fifty-two week high of $45.00. The stock's 50-day moving average is $11.35 and its 200-day moving average is $14.67.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.58) by $1.06. The business had revenue of $29.38 million for the quarter, compared to analysts' expectations of $25.64 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. As a group, equities research analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.22 EPS for the current year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.